vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and QUANTUM CORP (QMCO). Click either name above to swap in a different company.

QUANTUM CORP is the larger business by last-quarter revenue ($74.6M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). QUANTUM CORP runs the higher net margin — -37.3% vs -70.9%, a 33.6% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 2.8%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-5.6M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 2.1%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Quantum Corporation is a data storage, management, and protection company that provides technology to store, manage, archive, and protect video and unstructured data throughout the data life cycle. Their products are used by enterprises, media and entertainment companies, government agencies, data companies, and life science organizations. Quantum is headquartered in San Jose, California and has offices around the world.

CTKB vs QMCO — Head-to-Head

Bigger by revenue
QMCO
QMCO
1.2× larger
QMCO
$74.6M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+5.3% gap
CTKB
8.1%
2.8%
QMCO
Higher net margin
QMCO
QMCO
33.6% more per $
QMCO
-37.3%
-70.9%
CTKB
More free cash flow
CTKB
CTKB
$3.9M more FCF
CTKB
$-1.8M
$-5.6M
QMCO
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
2.1%
QMCO

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CTKB
CTKB
QMCO
QMCO
Revenue
$62.1M
$74.6M
Net Profit
$-44.1M
$-27.8M
Gross Margin
52.9%
38.8%
Operating Margin
-9.0%
-1.6%
Net Margin
-70.9%
-37.3%
Revenue YoY
8.1%
2.8%
Net Profit YoY
-557.1%
61.0%
EPS (diluted)
$-2.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
QMCO
QMCO
Q4 25
$62.1M
$74.6M
Q3 25
$52.3M
$62.7M
Q2 25
$45.6M
$64.3M
Q1 25
$41.5M
$61.3M
Q4 24
$57.5M
$68.7M
Q3 24
$51.5M
$71.8M
Q2 24
$46.6M
$72.3M
Q1 24
$44.9M
$71.5M
Net Profit
CTKB
CTKB
QMCO
QMCO
Q4 25
$-44.1M
$-27.8M
Q3 25
$-5.5M
$-46.5M
Q2 25
$-5.6M
$-17.2M
Q1 25
$-11.4M
$-7.7M
Q4 24
$9.6M
$-75.3M
Q3 24
$941.0K
$-12.2M
Q2 24
$-10.4M
$-19.9M
Q1 24
$-6.2M
$-18.9M
Gross Margin
CTKB
CTKB
QMCO
QMCO
Q4 25
52.9%
38.8%
Q3 25
52.7%
37.6%
Q2 25
52.3%
35.3%
Q1 25
48.6%
39.6%
Q4 24
58.5%
40.6%
Q3 24
56.3%
42.7%
Q2 24
54.6%
37.4%
Q1 24
51.3%
38.2%
Operating Margin
CTKB
CTKB
QMCO
QMCO
Q4 25
-9.0%
-1.6%
Q3 25
-17.6%
-13.0%
Q2 25
-23.3%
-19.6%
Q1 25
-36.1%
-18.9%
Q4 24
5.2%
-11.3%
Q3 24
-8.2%
-7.7%
Q2 24
-18.3%
-23.3%
Q1 24
-23.9%
-19.3%
Net Margin
CTKB
CTKB
QMCO
QMCO
Q4 25
-70.9%
-37.3%
Q3 25
-10.5%
-74.1%
Q2 25
-12.2%
-26.8%
Q1 25
-27.5%
-12.6%
Q4 24
16.8%
-109.6%
Q3 24
1.8%
-16.9%
Q2 24
-22.4%
-27.5%
Q1 24
-13.8%
-26.5%
EPS (diluted)
CTKB
CTKB
QMCO
QMCO
Q4 25
$-2.03
Q3 25
$-3.49
Q2 25
$-1.87
Q1 25
$-0.31
Q4 24
$-15.35
Q3 24
$-2.54
Q2 24
$-4.15
Q1 24
$-5.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
QMCO
QMCO
Cash + ST InvestmentsLiquidity on hand
$90.9M
$13.2M
Total DebtLower is stronger
$75.9M
Stockholders' EquityBook value
$341.7M
$-184.2M
Total Assets
$461.5M
$149.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
QMCO
QMCO
Q4 25
$90.9M
$13.2M
Q3 25
$93.3M
$14.7M
Q2 25
$75.5M
$37.4M
Q1 25
$95.3M
$16.5M
Q4 24
$98.7M
$20.4M
Q3 24
$162.3M
$16.7M
Q2 24
$177.9M
$17.3M
Q1 24
$168.8M
$25.7M
Total Debt
CTKB
CTKB
QMCO
QMCO
Q4 25
$75.9M
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$123.0M
Q2 24
$100.9M
Q1 24
$0
Stockholders' Equity
CTKB
CTKB
QMCO
QMCO
Q4 25
$341.7M
$-184.2M
Q3 25
$378.6M
$-160.5M
Q2 25
$377.6M
$-114.4M
Q1 25
$379.6M
$-164.4M
Q4 24
$395.7M
$-196.6M
Q3 24
$385.5M
$-151.1M
Q2 24
$389.1M
$-140.3M
Q1 24
$392.6M
$-121.5M
Total Assets
CTKB
CTKB
QMCO
QMCO
Q4 25
$461.5M
$149.3M
Q3 25
$494.9M
$137.7M
Q2 25
$493.3M
$169.2M
Q1 25
$482.6M
$155.4M
Q4 24
$499.5M
$168.1M
Q3 24
$491.2M
$163.1M
Q2 24
$483.7M
$173.1M
Q1 24
$492.1M
$187.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
QMCO
QMCO
Operating Cash FlowLast quarter
$-771.0K
$-4.9M
Free Cash FlowOCF − Capex
$-1.8M
$-5.6M
FCF MarginFCF / Revenue
-2.9%
-7.5%
Capex IntensityCapex / Revenue
1.6%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-43.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
QMCO
QMCO
Q4 25
$-771.0K
$-4.9M
Q3 25
$-3.9M
$-15.6M
Q2 25
$108.0K
$-16.9M
Q1 25
$-125.0K
$-3.3M
Q4 24
$2.0M
$-3.2M
Q3 24
$13.2M
$-15.3M
Q2 24
$6.2M
$-1.9M
Q1 24
$4.0M
$10.6M
Free Cash Flow
CTKB
CTKB
QMCO
QMCO
Q4 25
$-1.8M
$-5.6M
Q3 25
$-4.6M
$-16.0M
Q2 25
$-1.5M
$-18.1M
Q1 25
$-974.0K
$-3.9M
Q4 24
$1.1M
$-4.2M
Q3 24
$12.2M
$-16.9M
Q2 24
$5.2M
$-3.5M
Q1 24
$3.4M
$9.7M
FCF Margin
CTKB
CTKB
QMCO
QMCO
Q4 25
-2.9%
-7.5%
Q3 25
-8.7%
-25.5%
Q2 25
-3.2%
-28.1%
Q1 25
-2.3%
-6.4%
Q4 24
1.9%
-6.2%
Q3 24
23.7%
-23.5%
Q2 24
11.0%
-4.9%
Q1 24
7.6%
13.6%
Capex Intensity
CTKB
CTKB
QMCO
QMCO
Q4 25
1.6%
0.9%
Q3 25
1.3%
0.7%
Q2 25
3.5%
1.9%
Q1 25
2.0%
1.0%
Q4 24
1.6%
1.6%
Q3 24
2.0%
2.2%
Q2 24
2.3%
2.2%
Q1 24
1.3%
1.2%
Cash Conversion
CTKB
CTKB
QMCO
QMCO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
14.05×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

QMCO
QMCO

Secondary Storage Systems$30.6M41%
Service And Subscriptions$26.5M36%
Primary Storage Systems$10.1M14%
Subscriptions$4.4M6%
Royalty$1.6M2%

Related Comparisons